{
  "dataset": {
    "name": "Compounding Regulatory Tracker",
    "url": "https://nphla.com/trackers/compounding-regulatory-tracker",
    "description": "Official federal records on drug compounding — Federal Register rules, proposed rules and notices, FDA announcements and safety alerts, and FDA enforcement-report recalls — tagged to 503A, 503B, GLP-1 compounding, USP standards, peptides and enforcement.",
    "publisher": "National Pharmacy Health & Leadership Alliance",
    "howToCite": "National Pharmacy Health & Leadership Alliance (NPHLA). nphla.com. “Compounding Regulatory Tracker.” Updated Oct 1, 2026. https://nphla.com/trackers/compounding-regulatory-tracker. Accessed October 1, 2026.",
    "kind": "Compounding regulatory tracker (Federal Register / FDA)",
    "dataOrigin": "NPHLA analysis of public data",
    "jurisdiction": "United States (federal)",
    "methodology": "The Intelligence pipeline collects official records from the Federal Register API (including a dedicated FDA compounding search), FDA press announcements, MedWatch safety alerts and recall feeds, and openFDA enforcement reports (including a search for recalls of compounded drugs). Each record is classified against the knowledge graph by matching topic names and keywords in its title and summary.\n\nThis tracker lists records from primary sources tagged with a compounding topic. News and trade-press items are excluded.",
    "coverage": "U.S. federal records (FDA and the Federal Register) published since tracking of each source began. State board actions and documents FDA publishes only on its website, such as warning letters, are not yet included.",
    "limitations": "Classification is automatic and keyword-based: a record can be missed if it does not use the tracked terms, and a record can occasionally be tagged to a topic it mentions only in passing. Recall records name the firms involved exactly as FDA publishes them. Not legal advice — read the official document.",
    "updateFrequency": "Sources are checked every 1 to 6 hours depending on the source, as configured in the Source Registry.",
    "selection": "Official records (final rule, proposed rule, notice, recall, press release and safety alert) from primary sources tagged “503a”, “503b”, “glp1-compounding”, “usp-compounding”, “peptides” and “compounding-enforcement” in the NPHLA knowledge graph.",
    "systemCheckedAt": "2026-10-01T19:05:02.711Z",
    "editoriallyReviewedAt": null,
    "editorialReview": "pending",
    "generatedAt": "2026-10-01T19:24:24.697Z",
    "recordCount": 54,
    "notAdvice": "Professional information compiled from public sources. Not medical, legal or regulatory advice; always confirm in the primary source."
  },
  "columns": [
    {
      "key": "recordType",
      "label": "Record type"
    }
  ],
  "records": [
    {
      "key": "item:2",
      "record": "G. L. Mezzetta Inc. Announces Recall of Mezzetta Brand Golden Greek Peperoncini (Medium Heat) Due to Presence of Pest Contaminant in the Jar",
      "subtitle": null,
      "detail": "For generations, families have trusted Mezzetta products on their tables. We take that trust seriously, which is why we want to share what we know about a voluntary recall involving a specific lot of Mezzetta GOLDEN GREEK PEPERONCINI MEDIU…",
      "status": "Recall",
      "fields": {
        "recordType": "Recall",
        "publisher": "U.S. Food and Drug Administration",
        "classification": null,
        "firm": null,
        "recallNumber": null
      },
      "jurisdiction": "US",
      "date": "2026-09-26T22:17:00.000Z",
      "dateType": "Enforcement report date",
      "source": {
        "title": "G. L. Mezzetta Inc. Announces Recall of Mezzetta Brand Golden Greek Peperoncini (Medium Heat) Due to Presence of Pest Contaminant in the Jar",
        "url": "https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/g-l-mezzetta-inc-announces-recall-mezzetta-brand-golden-greek-peperoncini-medium-heat-due-presence",
        "publisher": "U.S. Food and Drug Administration",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:08.752Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:22.782Z",
      "change": {
        "note": "Recall published in the FDA Enforcement Report",
        "at": "2026-09-26T22:17:00.000Z",
        "withinLast7Days": true
      },
      "origin": "automated"
    },
    {
      "key": "item:21",
      "record": "Angiographic Catheter Recall: Boston Scientific Removes Imager II Angiographic Catheters",
      "subtitle": null,
      "detail": "Boston Scientific Imager II Angiographic Catheters removed due to a manufacturing issue leading to tip detachment; could result in procedural delays, embolism",
      "status": "Safety alert",
      "fields": {
        "recordType": "Safety alert",
        "publisher": "U.S. Food and Drug Administration (MedWatch)"
      },
      "jurisdiction": "US",
      "date": "2026-09-25T04:00:00.000Z",
      "dateType": "Published",
      "source": {
        "title": "Angiographic Catheter Recall: Boston Scientific Removes Imager II Angiographic Catheters",
        "url": "https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/angiographic-catheter-recall-boston-scientific-removes-imager-ii-angiographic-catheters",
        "publisher": "U.S. Food and Drug Administration (MedWatch)",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:09.176Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:24.060Z",
      "change": {
        "note": "Safety alert published",
        "at": "2026-09-25T04:00:00.000Z",
        "withinLast7Days": true
      },
      "origin": "automated"
    },
    {
      "key": "item:22",
      "record": "Heart Pump Controller Recall: Abiomed Removes Automated Impella Controllers",
      "subtitle": null,
      "detail": "Abiomed is removing Automated Impella Controllers due to purge cassette recognition failures that may lead to prolonged delayed in mechanical circulatory support.",
      "status": "Safety alert",
      "fields": {
        "recordType": "Safety alert",
        "publisher": "U.S. Food and Drug Administration (MedWatch)"
      },
      "jurisdiction": "US",
      "date": "2026-09-24T04:00:00.000Z",
      "dateType": "Published",
      "source": {
        "title": "Heart Pump Controller Recall: Abiomed Removes Automated Impella Controllers",
        "url": "https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/heart-pump-controller-recall-abiomed-removes-automated-impella-controllers",
        "publisher": "U.S. Food and Drug Administration (MedWatch)",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:09.176Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:23.910Z",
      "change": {
        "note": "Safety alert published",
        "at": "2026-09-24T04:00:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:41",
      "record": "Federal Court Enters Consent Decree Against Gold Star Distribution, Inc. Following Persistent Insanitary Warehouse Conditions",
      "subtitle": null,
      "detail": "A U.S. Food and Drug Administration investigation resulted in a federal court order, dated Sept. 21, 2026, stopping a warehouse operator from distributing FDA-regulated products including food, drugs, medical devices, and cosmetics until i…",
      "status": "Press release",
      "fields": {
        "recordType": "Press release",
        "publisher": "U.S. Food and Drug Administration"
      },
      "jurisdiction": "US",
      "date": "2026-09-23T19:50:17.000Z",
      "dateType": "Published",
      "source": {
        "title": "Federal Court Enters Consent Decree Against Gold Star Distribution, Inc. Following Persistent Insanitary Warehouse Conditions",
        "url": "https://www.fda.gov/news-events/press-announcements/federal-court-enters-consent-decree-against-gold-star-distribution-inc-following-persistent",
        "publisher": "U.S. Food and Drug Administration",
        "type": "Primary source"
      },
      "lastChecked": "2026-10-01T09:05:09.466Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:24.667Z",
      "change": {
        "note": "Press release published",
        "at": "2026-09-23T19:50:17.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:27",
      "record": "Ventilator Recall: CooperSurgical Removes INCA Infant Nasal CPAP Sets",
      "subtitle": null,
      "detail": "The cannula sets may exhibit a loose connection between the flexible tubing and the nasal cannula resulting in reduced effectiveness and decreased oxygenation.",
      "status": "Safety alert",
      "fields": {
        "recordType": "Safety alert",
        "publisher": "U.S. Food and Drug Administration (MedWatch)"
      },
      "jurisdiction": "US",
      "date": "2026-09-21T04:00:00.000Z",
      "dateType": "Published",
      "source": {
        "title": "Ventilator Recall: CooperSurgical Removes INCA Infant Nasal CPAP Sets",
        "url": "https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/ventilator-recall-coopersurgical-removes-inca-infant-nasal-cpap-sets",
        "publisher": "U.S. Food and Drug Administration (MedWatch)",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:09.176Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:23.651Z",
      "change": {
        "note": "Safety alert published",
        "at": "2026-09-21T04:00:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:8",
      "record": "Par Health Issues Voluntary Nationwide Recall of Two Lots of Dexmedetomidine HCl in 0.9% Sodium Chloride Injection Due to the Presence of Particulate Matter",
      "subtitle": null,
      "detail": "ROCHESTER, MI– September 18, 2026 –Par Health is voluntarily recalling two lots of Dexmedetomidine HCl in 0.9% Sodium Chloride Injection 400 mcg/100 mL (4 mcg/mL) to the hospital level. The product is being recalled due to the presence of…",
      "status": "Recall",
      "fields": {
        "recordType": "Recall",
        "publisher": "U.S. Food and Drug Administration",
        "classification": null,
        "firm": null,
        "recallNumber": null
      },
      "jurisdiction": "US",
      "date": "2026-09-18T19:14:00.000Z",
      "dateType": "Enforcement report date",
      "source": {
        "title": "Par Health Issues Voluntary Nationwide Recall of Two Lots of Dexmedetomidine HCl in 0.9% Sodium Chloride Injection Due to the Presence of Particulate Matter",
        "url": "https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/par-health-issues-voluntary-nationwide-recall-two-lots-dexmedetomidine-hcl-09-sodium-chloride",
        "publisher": "U.S. Food and Drug Administration",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:08.752Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:22.515Z",
      "change": {
        "note": "Recall published in the FDA Enforcement Report",
        "at": "2026-09-18T19:14:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:28",
      "record": "Sodium Chloride Flush Recall: Spectra Medical Removes Sodium Chloride Injection USP Ampules",
      "subtitle": null,
      "detail": "Spectra Medical Devices is removing Sodium Chloride Flush products that were manufactured by Huons Co,. Ltd.",
      "status": "Safety alert",
      "fields": {
        "recordType": "Safety alert",
        "publisher": "U.S. Food and Drug Administration (MedWatch)"
      },
      "jurisdiction": "US",
      "date": "2026-09-18T04:00:00.000Z",
      "dateType": "Published",
      "source": {
        "title": "Sodium Chloride Flush Recall: Spectra Medical Removes Sodium Chloride Injection USP Ampules",
        "url": "https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/sodium-chloride-flush-recall-spectra-medical-removes-sodium-chloride-injection-usp-ampules",
        "publisher": "U.S. Food and Drug Administration (MedWatch)",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:09.176Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:23.463Z",
      "change": {
        "note": "Safety alert published",
        "at": "2026-09-18T04:00:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:9",
      "record": "Otsuka ICU Medical LLC Issues Voluntary Nationwide Recall of 0.9% Sodium Chloride Injection, USP Due To a Product Mix-up with 10 mEq Potassium Chloride Injection",
      "subtitle": null,
      "detail": "Otsuka ICU Medical LLC is issuing a voluntary recall for one lot of 0.9% SODIUM CHLORIDE Injection, USP, 100mL single pack to the user level due to a potential mix-up. The affected lot of 0.9% SODIUM CHLORIDE Injection, USP (NDC: 0990-7984…",
      "status": "Recall",
      "fields": {
        "recordType": "Recall",
        "publisher": "U.S. Food and Drug Administration",
        "classification": null,
        "firm": null,
        "recallNumber": null
      },
      "jurisdiction": "US",
      "date": "2026-09-17T04:00:00.000Z",
      "dateType": "Enforcement report date",
      "source": {
        "title": "Otsuka ICU Medical LLC Issues Voluntary Nationwide Recall of 0.9% Sodium Chloride Injection, USP Due To a Product Mix-up with 10 mEq Potassium Chloride Injection",
        "url": "https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/otsuka-icu-medical-llc-issues-voluntary-nationwide-recall-09-sodium-chloride-injection-usp-due",
        "publisher": "U.S. Food and Drug Administration",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:08.752Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:22.366Z",
      "change": {
        "note": "Recall published in the FDA Enforcement Report",
        "at": "2026-09-17T04:00:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:11",
      "record": "So Delicious Dairy Free® Issues Voluntary Recall of Salted Caramel Cluster Non-Dairy Frozen Dessert Pints Due to Potential Presence of Foreign Material",
      "subtitle": null,
      "detail": "WHITE PLAINS, N.Y. and LOUISVILLE, Colo., September 15, 2026 – Danone USA is issuing a voluntary recall of So Delicious Dairy Free® Salted Caramel Cluster Non-Dairy Frozen Dessert pints with best-by dates on and before April 3, 2028 due to…",
      "status": "Recall",
      "fields": {
        "recordType": "Recall",
        "publisher": "U.S. Food and Drug Administration",
        "classification": null,
        "firm": null,
        "recallNumber": null
      },
      "jurisdiction": "US",
      "date": "2026-09-15T20:31:00.000Z",
      "dateType": "Enforcement report date",
      "source": {
        "title": "So Delicious Dairy Free® Issues Voluntary Recall of Salted Caramel Cluster Non-Dairy Frozen Dessert Pints Due to Potential Presence of Foreign Material",
        "url": "https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/so-delicious-dairy-freer-issues-voluntary-recall-salted-caramel-cluster-non-dairy-frozen-dessert",
        "publisher": "U.S. Food and Drug Administration",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:08.752Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:22.194Z",
      "change": {
        "note": "Recall published in the FDA Enforcement Report",
        "at": "2026-09-15T20:31:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:30",
      "record": "Esophageal pH Monitoring Capsule Recall: Medtronic and Given Imaging Remove Esophageal pH Monitoring Capsule Delivery Device",
      "subtitle": null,
      "detail": "The Medtronic and Given Imaging Bravo CF esophageal pH monitoring capsule can fail to attach to the esophagus or detach from its delivery device.",
      "status": "Safety alert",
      "fields": {
        "recordType": "Safety alert",
        "publisher": "U.S. Food and Drug Administration (MedWatch)"
      },
      "jurisdiction": "US",
      "date": "2026-09-15T04:00:00.000Z",
      "dateType": "Published",
      "source": {
        "title": "Esophageal pH Monitoring Capsule Recall: Medtronic and Given Imaging Remove Esophageal pH Monitoring Capsule Delivery Device",
        "url": "https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/esophageal-ph-monitoring-capsule-recall-medtronic-and-given-imaging-remove-esophageal-ph-monitoring",
        "publisher": "U.S. Food and Drug Administration (MedWatch)",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:09.176Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:23.259Z",
      "change": {
        "note": "Safety alert published",
        "at": "2026-09-15T04:00:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:13",
      "record": "A&P Creations LLC Issues Nationwide Recall of biQ-FEL Due to Undeclared Sildenafil and Tadalafil",
      "subtitle": null,
      "detail": "Sildenafil and Tadalafil are active ingredients in FDA-approved prescription drugs Viagra and Cialis, respectively, used to treat erectile dysfunction. FDA approval of Viagra and Cialis is restricted to use under the supervision of a licen…",
      "status": "Recall",
      "fields": {
        "recordType": "Recall",
        "publisher": "U.S. Food and Drug Administration",
        "classification": null,
        "firm": null,
        "recallNumber": null
      },
      "jurisdiction": "US",
      "date": "2026-09-14T19:55:00.000Z",
      "dateType": "Enforcement report date",
      "source": {
        "title": "A&P Creations LLC Issues Nationwide Recall of biQ-FEL Due to Undeclared Sildenafil and Tadalafil",
        "url": "https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/ap-creations-llc-issues-nationwide-recall-biq-fel-due-undeclared-sildenafil-and-tadalafil",
        "publisher": "U.S. Food and Drug Administration",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:08.752Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:22.012Z",
      "change": {
        "note": "Recall published in the FDA Enforcement Report",
        "at": "2026-09-14T19:55:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:14",
      "record": "A&P Creations LLC Issues Nationwide Recall of X10 Natural Enhancement Supplement Due to Undeclared Sildenafil and Tadalafil",
      "subtitle": null,
      "detail": "Clermont, Florida – A&P Creations LLC is recalling X10 Natural Enhancement Supplement to the consumer level because it has been found to contain undeclared sildenafil and tadalafil.",
      "status": "Recall",
      "fields": {
        "recordType": "Recall",
        "publisher": "U.S. Food and Drug Administration",
        "classification": null,
        "firm": null,
        "recallNumber": null
      },
      "jurisdiction": "US",
      "date": "2026-09-14T19:06:00.000Z",
      "dateType": "Enforcement report date",
      "source": {
        "title": "A&P Creations LLC Issues Nationwide Recall of X10 Natural Enhancement Supplement Due to Undeclared Sildenafil and Tadalafil",
        "url": "https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/ap-creations-llc-issues-nationwide-recall-x10-natural-enhancement-supplement-due-undeclared",
        "publisher": "U.S. Food and Drug Administration",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:08.752Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:21.796Z",
      "change": {
        "note": "Recall published in the FDA Enforcement Report",
        "at": "2026-09-14T19:06:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:17",
      "record": "Centric Compounding Issues Nationwide Recall of Glutathione, Myer’s Cocktail, and Tri-Immune Boost Due to Elevated Endotoxin Levels",
      "subtitle": null,
      "detail": "FOR IMMEDIATE RELEASE – 9/9/2026 – Houston, Texas, Centric Compounding is voluntarily recalling 6 lots of Glutathione 200mg/mL, Myer’s Cocktail, and Tri-Immune Boost injectable vials to the consumer level. The products have been found to b…",
      "status": "Recall",
      "fields": {
        "recordType": "Recall",
        "publisher": "U.S. Food and Drug Administration",
        "classification": null,
        "firm": null,
        "recallNumber": null
      },
      "jurisdiction": "US",
      "date": "2026-09-11T15:00:00.000Z",
      "dateType": "Enforcement report date",
      "source": {
        "title": "Centric Compounding Issues Nationwide Recall of Glutathione, Myer’s Cocktail, and Tri-Immune Boost Due to Elevated Endotoxin Levels",
        "url": "https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/centric-compounding-issues-nationwide-recall-glutathione-myers-cocktail-and-tri-immune-boost-due",
        "publisher": "U.S. Food and Drug Administration",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:08.752Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:21.562Z",
      "change": {
        "note": "Recall published in the FDA Enforcement Report",
        "at": "2026-09-11T15:00:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:154",
      "record": "Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates; Guidance for Industry; Availability",
      "subtitle": "Health and Human Services Department, Food and Drug Administration",
      "detail": "The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a guidance for industry titled \"Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates.\" This guidance desc…",
      "status": "Notice",
      "fields": {
        "recordType": "Notice",
        "publisher": "Federal Register",
        "documentNumber": "2026-18368",
        "agencies": "Health and Human Services Department, Food and Drug Administration"
      },
      "jurisdiction": "US",
      "date": "2026-09-09T00:00:00.000Z",
      "dateType": "Published in the Federal Register",
      "source": {
        "title": "Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates; Guidance for Industry; Availability",
        "url": "https://www.federalregister.gov/documents/2026/09/09/2026-18368/temporary-policies-for-compounding-certain-starter-parenteral-nutrition-drug-products-for-neonates",
        "publisher": "Federal Register",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:13.506Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:30.576Z",
      "change": {
        "note": "Notice published",
        "at": "2026-09-09T00:00:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:19",
      "record": "FreshPoint Issues Recall Due to an Improperly Declared Allergen (Egg) in Chicken Salad Wedge Sandwiches",
      "subtitle": null,
      "detail": "September 4, 2026 Orlando, FL– FreshPoint of Orlando, FL., is issuing a voluntary recall of 1,093 units of specific lots of Cranberry Chicken Salad Wedge sandwiches due to an improperly declared allergen (eggs). People who have an allergy…",
      "status": "Recall",
      "fields": {
        "recordType": "Recall",
        "publisher": "U.S. Food and Drug Administration",
        "classification": null,
        "firm": null,
        "recallNumber": null
      },
      "jurisdiction": "US",
      "date": "2026-09-08T19:31:00.000Z",
      "dateType": "Enforcement report date",
      "source": {
        "title": "FreshPoint Issues Recall Due to an Improperly Declared Allergen (Egg) in Chicken Salad Wedge Sandwiches",
        "url": "https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/freshpoint-issues-recall-due-improperly-declared-allergen-egg-chicken-salad-wedge-sandwiches",
        "publisher": "U.S. Food and Drug Administration",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:08.752Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:21.295Z",
      "change": {
        "note": "Recall published in the FDA Enforcement Report",
        "at": "2026-09-08T19:31:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:20",
      "record": "BMC Medical Co., Ltd. Recalls Luna G3 APAP (Model LG3600) with Firmware G3-2.00.76 Due to Firmware Defect",
      "subtitle": null,
      "detail": "On July 15, 2026, BMC Medical Co., Ltd. (BMC), Beijing, China, retrospectively reported to the US Food and Drug Administration (FDA) a recall of 20,160 Luna G3 APAP (Model LG3600) devices distributed in the United States due to firmware de…",
      "status": "Recall",
      "fields": {
        "recordType": "Recall",
        "publisher": "U.S. Food and Drug Administration",
        "classification": null,
        "firm": null,
        "recallNumber": null
      },
      "jurisdiction": "US",
      "date": "2026-09-07T14:55:00.000Z",
      "dateType": "Enforcement report date",
      "source": {
        "title": "BMC Medical Co., Ltd. Recalls Luna G3 APAP (Model LG3600) with Firmware G3-2.00.76 Due to Firmware Defect",
        "url": "https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/bmc-medical-co-ltd-recalls-luna-g3-apap-model-lg3600-firmware-g3-20076-due-firmware-defect",
        "publisher": "U.S. Food and Drug Administration",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:08.752Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:21.235Z",
      "change": {
        "note": "Recall published in the FDA Enforcement Report",
        "at": "2026-09-07T14:55:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:33",
      "record": "Spinal Cord Stimulator Recall: Boston Scientific Removes Infinion CX Lead",
      "subtitle": null,
      "detail": "Infinion CX Lead bodies may experience mechanical stress at the anchor site resulting in inadequate stimulation requiring lead explant and replacement.",
      "status": "Safety alert",
      "fields": {
        "recordType": "Safety alert",
        "publisher": "U.S. Food and Drug Administration (MedWatch)"
      },
      "jurisdiction": "US",
      "date": "2026-09-03T04:00:00.000Z",
      "dateType": "Published",
      "source": {
        "title": "Spinal Cord Stimulator Recall: Boston Scientific Removes Infinion CX Lead",
        "url": "https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/spinal-cord-stimulator-recall-boston-scientific-removes-infinion-cx-lead",
        "publisher": "U.S. Food and Drug Administration (MedWatch)",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:09.176Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:23.039Z",
      "change": {
        "note": "Safety alert published",
        "at": "2026-09-03T04:00:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:32",
      "record": "B. Braun Medical Inc. Issues Voluntary Nationwide Recall of 0.9% Sodium Chloride Injection USP, 100 mL, in a 150 mL PAB® Container Due to the Presence of Particulate Matter",
      "subtitle": null,
      "detail": "FOR IMMEDIATE RELEASE – September 3, 2026– Bethlehem, PA, B. Braun Medical Inc (B. Braun) is voluntarily recalling three (3) lots of 0.9% Sodium Chloride Injection USP, 100 mL, in a 150 mL PAB® Container, to the hospital/healthcare facilit…",
      "status": "Safety alert",
      "fields": {
        "recordType": "Safety alert",
        "publisher": "U.S. Food and Drug Administration (MedWatch)"
      },
      "jurisdiction": "US",
      "date": "2026-09-03T04:00:00.000Z",
      "dateType": "Published",
      "source": {
        "title": "B. Braun Medical Inc. Issues Voluntary Nationwide Recall of 0.9% Sodium Chloride Injection USP, 100 mL, in a 150 mL PAB® Container Due to the Presence of Particulate Matter",
        "url": "https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/b-braun-medical-inc-issues-voluntary-nationwide-recall-09-sodium-chloride-injection-usp-100-ml-150",
        "publisher": "U.S. Food and Drug Administration (MedWatch)",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:09.176Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:23.078Z",
      "change": {
        "note": "Safety alert published",
        "at": "2026-09-03T04:00:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:36",
      "record": "Catheter Recall Expansion: Medline Industries Removes Reprocessed Electrophysiology and Ultrasound Catheters",
      "subtitle": null,
      "detail": "Certain reprocessed catheters may contain residual particulates that could cause infection, embolism, or thrombosis",
      "status": "Safety alert",
      "fields": {
        "recordType": "Safety alert",
        "publisher": "U.S. Food and Drug Administration (MedWatch)"
      },
      "jurisdiction": "US",
      "date": "2026-09-02T04:00:00.000Z",
      "dateType": "Published",
      "source": {
        "title": "Catheter Recall Expansion: Medline Industries Removes Reprocessed Electrophysiology and Ultrasound Catheters",
        "url": "https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/catheter-recall-expansion-medline-industries-removes-reprocessed-electrophysiology-and-ultrasound",
        "publisher": "U.S. Food and Drug Administration (MedWatch)",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:09.176Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:22.861Z",
      "change": {
        "note": "Safety alert published",
        "at": "2026-09-02T04:00:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:191",
      "record": "Agency Information Collection Activities; Proposed Collection; Comment Request; Registration of Human Drug Compounding Outsourcing Facilities Under the Federal Food, Drug, and Cosmetic Act and Associated Fees",
      "subtitle": "Health and Human Services Department, Food and Drug Administration",
      "detail": "The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are require…",
      "status": "Notice",
      "fields": {
        "recordType": "Notice",
        "publisher": "Federal Register",
        "documentNumber": "2026-17676",
        "agencies": "Health and Human Services Department, Food and Drug Administration"
      },
      "jurisdiction": "US",
      "date": "2026-08-31T00:00:00.000Z",
      "dateType": "Published in the Federal Register",
      "source": {
        "title": "Agency Information Collection Activities; Proposed Collection; Comment Request; Registration of Human Drug Compounding Outsourcing Facilities Under the Federal Food, Drug, and Cosmetic Act and Associated Fees",
        "url": "https://www.federalregister.gov/documents/2026/08/31/2026-17676/agency-information-collection-activities-proposed-collection-comment-request-registration-of-human",
        "publisher": "Federal Register",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:14.175Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:31.914Z",
      "change": {
        "note": "Notice published",
        "at": "2026-08-31T00:00:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:156",
      "record": "Compounding Animal Drugs From Bulk Drug Substances: Compounding Under CGMP in Federally-Registered Facilities; Draft Guidance for Industry; Availability; Agency Information Collection Activities; Proposed Collection; Comment Request",
      "subtitle": "Health and Human Services Department, Food and Drug Administration",
      "detail": "The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft guidance for industry (GFI) #256B entitled \"Compounding Animal Drugs from Bulk Drug Substances: Compounding under CGMP in Federally-Registered…",
      "status": "Notice",
      "fields": {
        "recordType": "Notice",
        "publisher": "Federal Register",
        "documentNumber": "2026-17580",
        "agencies": "Health and Human Services Department, Food and Drug Administration"
      },
      "jurisdiction": "US",
      "date": "2026-08-28T00:00:00.000Z",
      "dateType": "Published in the Federal Register",
      "source": {
        "title": "Compounding Animal Drugs From Bulk Drug Substances: Compounding Under CGMP in Federally-Registered Facilities; Draft Guidance for Industry; Availability; Agency Information Collection Activities; Proposed Collection; Comment Request",
        "url": "https://www.federalregister.gov/documents/2026/08/28/2026-17580/compounding-animal-drugs-from-bulk-drug-substances-compounding-under-cgmp-in-federally-registered",
        "publisher": "Federal Register",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:13.506Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:30.477Z",
      "change": {
        "note": "Notice published",
        "at": "2026-08-28T00:00:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:101",
      "record": "SEMAGLUTIDE 5mg (1mg/mL), Glycine 25 mg (5mg/mL), 5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102,…",
      "subtitle": "Recall D-0754-2026",
      "detail": "Reason: Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material",
      "status": "Class II · Ongoing",
      "fields": {
        "recordType": "Recall",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "classification": "Class II",
        "firm": "Apollo Care, LLC",
        "recallNumber": "D-0754-2026"
      },
      "jurisdiction": "US",
      "date": "2026-08-19T00:00:00.000Z",
      "dateType": "Enforcement report date",
      "source": {
        "title": "Class II recall: SEMAGLUTIDE 5mg (1mg/mL), Glycine 25 mg (5mg/mL), 5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous…",
        "url": "https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0754-2026%22",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:12.028Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:27.731Z",
      "change": {
        "note": "Recall published in the FDA Enforcement Report",
        "at": "2026-08-19T00:00:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:100",
      "record": "SEMAGLUTIDE 4.5mg (0.9 mg/mL), 5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202…",
      "subtitle": "Recall D-0750-2026",
      "detail": "Reason: Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material",
      "status": "Class II · Ongoing",
      "fields": {
        "recordType": "Recall",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "classification": "Class II",
        "firm": "Apollo Care, LLC",
        "recallNumber": "D-0750-2026"
      },
      "jurisdiction": "US",
      "date": "2026-08-19T00:00:00.000Z",
      "dateType": "Enforcement report date",
      "source": {
        "title": "Class II recall: SEMAGLUTIDE 4.5mg (0.9 mg/mL), 5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only,…",
        "url": "https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0750-2026%22",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:12.028Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:27.778Z",
      "change": {
        "note": "Recall published in the FDA Enforcement Report",
        "at": "2026-08-19T00:00:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:99",
      "record": "SEMAGLUTIDE 9mg (4.5 mg/mL), 2 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202.…",
      "subtitle": "Recall D-0751-2026",
      "detail": "Reason: Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material",
      "status": "Class II · Ongoing",
      "fields": {
        "recordType": "Recall",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "classification": "Class II",
        "firm": "Apollo Care, LLC",
        "recallNumber": "D-0751-2026"
      },
      "jurisdiction": "US",
      "date": "2026-08-19T00:00:00.000Z",
      "dateType": "Enforcement report date",
      "source": {
        "title": "Class II recall: SEMAGLUTIDE 9mg (4.5 mg/mL), 2 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO…",
        "url": "https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0751-2026%22",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:12.028Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:27.817Z",
      "change": {
        "note": "Recall published in the FDA Enforcement Report",
        "at": "2026-08-19T00:00:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:98",
      "record": "SEMAGLUTIDE 10mg (5mg/mL), Glycine 10 mg (5mg/mL), 2 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102…",
      "subtitle": "Recall D-0756-2026",
      "detail": "Reason: Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material",
      "status": "Class II · Ongoing",
      "fields": {
        "recordType": "Recall",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "classification": "Class II",
        "firm": "Apollo Care, LLC",
        "recallNumber": "D-0756-2026"
      },
      "jurisdiction": "US",
      "date": "2026-08-19T00:00:00.000Z",
      "dateType": "Enforcement report date",
      "source": {
        "title": "Class II recall: SEMAGLUTIDE 10mg (5mg/mL), Glycine 10 mg (5mg/mL), 2 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous…",
        "url": "https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0756-2026%22",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:12.028Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:27.855Z",
      "change": {
        "note": "Recall published in the FDA Enforcement Report",
        "at": "2026-08-19T00:00:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:97",
      "record": "SEMAGLUTIDE 20mg (5mg/mL), Glycine 20 mg (5mg/mL), 4 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102…",
      "subtitle": "Recall D-0757-2026",
      "detail": "Reason: Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material",
      "status": "Class II · Ongoing",
      "fields": {
        "recordType": "Recall",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "classification": "Class II",
        "firm": "Apollo Care, LLC",
        "recallNumber": "D-0757-2026"
      },
      "jurisdiction": "US",
      "date": "2026-08-19T00:00:00.000Z",
      "dateType": "Enforcement report date",
      "source": {
        "title": "Class II recall: SEMAGLUTIDE 20mg (5mg/mL), Glycine 20 mg (5mg/mL), 4 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous…",
        "url": "https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0757-2026%22",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:12.028Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:27.895Z",
      "change": {
        "note": "Recall published in the FDA Enforcement Report",
        "at": "2026-08-19T00:00:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:96",
      "record": "SEMAGLUTIDE 0.9mg (0.9 mg/mL), 1 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202…",
      "subtitle": "Recall D-0752-2026",
      "detail": "Reason: Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material",
      "status": "Class II · Ongoing",
      "fields": {
        "recordType": "Recall",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "classification": "Class II",
        "firm": "Apollo Care, LLC",
        "recallNumber": "D-0752-2026"
      },
      "jurisdiction": "US",
      "date": "2026-08-19T00:00:00.000Z",
      "dateType": "Enforcement report date",
      "source": {
        "title": "Class II recall: SEMAGLUTIDE 0.9mg (0.9 mg/mL), 1 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only,…",
        "url": "https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0752-2026%22",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:12.028Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:27.939Z",
      "change": {
        "note": "Recall published in the FDA Enforcement Report",
        "at": "2026-08-19T00:00:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:95",
      "record": "SEMAGLUTIDE 6.75mg (4.5 mg/mL), 1.5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65…",
      "subtitle": "Recall D-0749-2026",
      "detail": "Reason: Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material",
      "status": "Class II · Ongoing",
      "fields": {
        "recordType": "Recall",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "classification": "Class II",
        "firm": "Apollo Care, LLC",
        "recallNumber": "D-0749-2026"
      },
      "jurisdiction": "US",
      "date": "2026-08-19T00:00:00.000Z",
      "dateType": "Enforcement report date",
      "source": {
        "title": "Class II recall: SEMAGLUTIDE 6.75mg (4.5 mg/mL), 1.5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only,…",
        "url": "https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0749-2026%22",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:12.028Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:27.982Z",
      "change": {
        "note": "Recall published in the FDA Enforcement Report",
        "at": "2026-08-19T00:00:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:94",
      "record": "SEMAGLUTIDE 2.5mg (1mg/mL), Glycine 12.5 mg (5mg/mL), 2.5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801Mojave Ct, Ste…",
      "subtitle": "Recall D-0753-2026",
      "detail": "Reason: Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material",
      "status": "Class II · Ongoing",
      "fields": {
        "recordType": "Recall",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "classification": "Class II",
        "firm": "Apollo Care, LLC",
        "recallNumber": "D-0753-2026"
      },
      "jurisdiction": "US",
      "date": "2026-08-19T00:00:00.000Z",
      "dateType": "Enforcement report date",
      "source": {
        "title": "Class II recall: SEMAGLUTIDE 2.5mg (1mg/mL), Glycine 12.5 mg (5mg/mL), 2.5 mL Sterile Multi-Dose Vial, Rx Only, For…",
        "url": "https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0753-2026%22",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:12.028Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:28.021Z",
      "change": {
        "note": "Recall published in the FDA Enforcement Report",
        "at": "2026-08-19T00:00:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:93",
      "record": "SEMAGLUTIDE 2.25MG (0.9 mg/mL), 2.5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65…",
      "subtitle": "Recall D-0748-2026",
      "detail": "Reason: Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material",
      "status": "Class II · Ongoing",
      "fields": {
        "recordType": "Recall",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "classification": "Class II",
        "firm": "Apollo Care, LLC",
        "recallNumber": "D-0748-2026"
      },
      "jurisdiction": "US",
      "date": "2026-08-19T00:00:00.000Z",
      "dateType": "Enforcement report date",
      "source": {
        "title": "Class II recall: SEMAGLUTIDE 2.25MG (0.9 mg/mL), 2.5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only,…",
        "url": "https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0748-2026%22",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:12.028Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:28.062Z",
      "change": {
        "note": "Recall published in the FDA Enforcement Report",
        "at": "2026-08-19T00:00:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:92",
      "record": "SEMAGLUTIDE 12.5MG (2.5MG/mL), 5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202…",
      "subtitle": "Recall D-0747-2026",
      "detail": "Reason: Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material",
      "status": "Class II · Ongoing",
      "fields": {
        "recordType": "Recall",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "classification": "Class II",
        "firm": "Apollo Care, LLC",
        "recallNumber": "D-0747-2026"
      },
      "jurisdiction": "US",
      "date": "2026-08-19T00:00:00.000Z",
      "dateType": "Enforcement report date",
      "source": {
        "title": "Class II recall: SEMAGLUTIDE 12.5MG (2.5MG/mL), 5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only,…",
        "url": "https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0747-2026%22",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:12.028Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:28.101Z",
      "change": {
        "note": "Recall published in the FDA Enforcement Report",
        "at": "2026-08-19T00:00:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:91",
      "record": "SEMAGLUTIDE 7.5mg (5mg/mL), Glycine 7.5 mg (5mg/mL), 1.5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste…",
      "subtitle": "Recall D-0755-2026",
      "detail": "Reason: Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material",
      "status": "Class II · Ongoing",
      "fields": {
        "recordType": "Recall",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "classification": "Class II",
        "firm": "Apollo Care, LLC",
        "recallNumber": "D-0755-2026"
      },
      "jurisdiction": "US",
      "date": "2026-08-19T00:00:00.000Z",
      "dateType": "Enforcement report date",
      "source": {
        "title": "Class II recall: SEMAGLUTIDE 7.5mg (5mg/mL), Glycine 7.5 mg (5mg/mL), 1.5 mL Sterile Multi-Dose Vial, Rx Only, For…",
        "url": "https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0755-2026%22",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:12.028Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:28.136Z",
      "change": {
        "note": "Recall published in the FDA Enforcement Report",
        "at": "2026-08-19T00:00:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:197",
      "record": "Outsourcing Facility Fee Rates for Fiscal Year 2027",
      "subtitle": "Health and Human Services Department, Food and Drug Administration",
      "detail": "The Food and Drug Administration (FDA or we) is announcing the fiscal year (FY) 2027 rates for the establishment and reinspection fees related to entities that compound human drugs and elect to register as outsourcing facilities under the…",
      "status": "Notice",
      "fields": {
        "recordType": "Notice",
        "publisher": "Federal Register",
        "documentNumber": "2026-15342",
        "agencies": "Health and Human Services Department, Food and Drug Administration"
      },
      "jurisdiction": "US",
      "date": "2026-07-30T00:00:00.000Z",
      "dateType": "Published in the Federal Register",
      "source": {
        "title": "Outsourcing Facility Fee Rates for Fiscal Year 2027",
        "url": "https://www.federalregister.gov/documents/2026/07/30/2026-15342/outsourcing-facility-fee-rates-for-fiscal-year-2027",
        "publisher": "Federal Register",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:14.175Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:31.676Z",
      "change": {
        "note": "Notice published",
        "at": "2026-07-30T00:00:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:102",
      "record": "Liraglutide Injection, 18 mg/3 mL (6 mg/mL), Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Naples, FL 34108, Manufactured by: Lupin Limited, Nagpur 4…",
      "subtitle": "Recall D-0541-2026",
      "detail": "Reason: Presence of particulate matter: a white thread-like structure in the cartridge",
      "status": "Class II · Ongoing",
      "fields": {
        "recordType": "Recall",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "classification": "Class II",
        "firm": "Lupin Pharmaceuticals Inc.",
        "recallNumber": "D-0541-2026"
      },
      "jurisdiction": "US",
      "date": "2026-05-27T00:00:00.000Z",
      "dateType": "Enforcement report date",
      "source": {
        "title": "Class II recall: Liraglutide Injection, 18 mg/3 mL (6 mg/mL), Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Naples,…",
        "url": "https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0541-2026%22",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:12.028Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:27.678Z",
      "change": {
        "note": "Recall published in the FDA Enforcement Report",
        "at": "2026-05-27T00:00:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:166",
      "record": "Agency Information Collection Activities; Proposed Collection; Comment Request; Human Drug Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act",
      "subtitle": "Health and Human Services Department, Food and Drug Administration",
      "detail": "The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are require…",
      "status": "Notice",
      "fields": {
        "recordType": "Notice",
        "publisher": "Federal Register",
        "documentNumber": "2026-10372",
        "agencies": "Health and Human Services Department, Food and Drug Administration"
      },
      "jurisdiction": "US",
      "date": "2026-05-26T00:00:00.000Z",
      "dateType": "Published in the Federal Register",
      "source": {
        "title": "Agency Information Collection Activities; Proposed Collection; Comment Request; Human Drug Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act",
        "url": "https://www.federalregister.gov/documents/2026/05/26/2026-10372/agency-information-collection-activities-proposed-collection-comment-request-human-drug-compounding",
        "publisher": "Federal Register",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:13.506Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:30.041Z",
      "change": {
        "note": "Notice published",
        "at": "2026-05-26T00:00:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:169",
      "record": "List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act",
      "subtitle": "Health and Human Services Department, Food and Drug Administration",
      "detail": "The Food and Drug Administration (FDA, the Agency, or we) is evaluating substances that have been nominated for inclusion on a list of bulk drug substances (active pharmaceutical ingredients) for which there is a clinical need for outsourc…",
      "status": "Notice",
      "fields": {
        "recordType": "Notice",
        "publisher": "Federal Register",
        "documentNumber": "2026-08552",
        "agencies": "Health and Human Services Department, Food and Drug Administration"
      },
      "jurisdiction": "US",
      "date": "2026-05-01T00:00:00.000Z",
      "dateType": "Published in the Federal Register",
      "source": {
        "title": "List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act",
        "url": "https://www.federalregister.gov/documents/2026/05/01/2026-08552/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal",
        "publisher": "Federal Register",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:13.506Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:29.894Z",
      "change": {
        "note": "Notice published",
        "at": "2026-05-01T00:00:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:103",
      "record": "Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, Northwest Compounders, Beaverton, OR",
      "subtitle": "Recall D-0471-2026",
      "detail": "Reason: Lack of Assurance of Sterility",
      "status": "Class II · Ongoing",
      "fields": {
        "recordType": "Recall",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "classification": "Class II",
        "firm": "PAYLESS COMPOUNDERS, LLC",
        "recallNumber": "D-0471-2026"
      },
      "jurisdiction": "US",
      "date": "2026-04-22T00:00:00.000Z",
      "dateType": "Enforcement report date",
      "source": {
        "title": "Class II recall: Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, Northwest…",
        "url": "https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0471-2026%22",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:12.028Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:27.641Z",
      "change": {
        "note": "Recall published in the FDA Enforcement Report",
        "at": "2026-04-22T00:00:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:105",
      "record": "Semaglutide Inj., 2 mg x 5, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, KS 66061, NDC 84223-001-06",
      "subtitle": "Recall D-0393-2026",
      "detail": "Reason: Lack of Assurance of Sterility",
      "status": "Class II · Ongoing",
      "fields": {
        "recordType": "Recall",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "classification": "Class II",
        "firm": "New Life Pharma LLC",
        "recallNumber": "D-0393-2026"
      },
      "jurisdiction": "US",
      "date": "2026-03-11T00:00:00.000Z",
      "dateType": "Enforcement report date",
      "source": {
        "title": "Class II recall: Semaglutide Inj., 2 mg x 5, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106,…",
        "url": "https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0393-2026%22",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:12.028Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:27.571Z",
      "change": {
        "note": "Recall published in the FDA Enforcement Report",
        "at": "2026-03-11T00:00:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:104",
      "record": "Semaglutide,  For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03; d)…",
      "subtitle": "Recall D-0380-2026",
      "detail": "Reason: CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution",
      "status": "Class II · Ongoing",
      "fields": {
        "recordType": "Recall",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "classification": "Class II",
        "firm": "Harbin Jixianglong Biotech Co., Ltd.",
        "recallNumber": "D-0380-2026"
      },
      "jurisdiction": "US",
      "date": "2026-03-11T00:00:00.000Z",
      "dateType": "Enforcement report date",
      "source": {
        "title": "Class II recall: Semaglutide,  For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c)…",
        "url": "https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0380-2026%22",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:12.028Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:27.607Z",
      "change": {
        "note": "Recall published in the FDA Enforcement Report",
        "at": "2026-03-11T00:00:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:106",
      "record": "PERIPHERAL PARENTERAL NUTRITION, Compounded Sterile Preparation, Refrigerated Injection, Rx Only, Single Dose Injection, a) 1440 mL bag, b) 1700 mL bag, Centra…",
      "subtitle": "Recall D-0530-2025",
      "detail": "Reason: Lack of Processing Controls; prescriptions were compounded in an ISO-5 area where it was identified that a daily cleaning step was not sufficiently documented.",
      "status": "Class II · Ongoing",
      "fields": {
        "recordType": "Recall",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "classification": "Class II",
        "firm": "Central Admixture Pharmacy Services, Inc (CAPS)  Los Angeles",
        "recallNumber": "D-0530-2025"
      },
      "jurisdiction": "US",
      "date": "2025-07-23T00:00:00.000Z",
      "dateType": "Enforcement report date",
      "source": {
        "title": "Class II recall: PERIPHERAL PARENTERAL NUTRITION, Compounded Sterile Preparation, Refrigerated Injection, Rx Only, Single…",
        "url": "https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0530-2025%22",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:12.440Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:28.714Z",
      "change": {
        "note": "Recall published in the FDA Enforcement Report",
        "at": "2025-07-23T00:00:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:107",
      "record": "HYDROmorphone Hydrochloride 50mg/50mL (1mg/mL), packaged in a 50 mL Cassette, Rx Only, OurPharma, LLC, 2512 S. City Lake Rd., Fayetteville, AR 72701,  NDC 7301…",
      "subtitle": "Recall D-0385-2025",
      "detail": "Reason: Superpotent Drug: Assay/potency result for hydromorphone HCl in the compounded stability lot was higher than specification..",
      "status": "Class III · Terminated",
      "fields": {
        "recordType": "Recall",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "classification": "Class III",
        "firm": "OurPharma LLC",
        "recallNumber": "D-0385-2025"
      },
      "jurisdiction": "US",
      "date": "2025-04-30T00:00:00.000Z",
      "dateType": "Enforcement report date",
      "source": {
        "title": "Class III recall: HYDROmorphone Hydrochloride 50mg/50mL (1mg/mL), packaged in a 50 mL Cassette, Rx Only, OurPharma, LLC, 2512…",
        "url": "https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0385-2025%22",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:12.440Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:28.676Z",
      "change": {
        "note": "Recall published in the FDA Enforcement Report",
        "at": "2025-04-30T00:00:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:108",
      "record": "Phenylephrine HCl 20 mg added to 0.9% Sodium Chloride 250mL Bag, Rx Only, Compounded by: Advanced Compounding Solutions, 4 Constitution Way Ste L Woburn, Massa…",
      "subtitle": "Recall D-0778-2023",
      "detail": "Reason: Product Mix up; Product was compounded in 250 mL 5% Dextrose instead of 250 mL 0.9% Sodium Chloride",
      "status": "Class III · Terminated",
      "fields": {
        "recordType": "Recall",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "classification": "Class III",
        "firm": "New England Life Care, Inc. dba Advanced Compounding Solutions",
        "recallNumber": "D-0778-2023"
      },
      "jurisdiction": "US",
      "date": "2023-06-07T00:00:00.000Z",
      "dateType": "Enforcement report date",
      "source": {
        "title": "Class III recall: Phenylephrine HCl 20 mg added to 0.9% Sodium Chloride 250mL Bag, Rx Only, Compounded by: Advanced…",
        "url": "https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0778-2023%22",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:12.440Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:28.633Z",
      "change": {
        "note": "Recall published in the FDA Enforcement Report",
        "at": "2023-06-07T00:00:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:120",
      "record": "Sildenafil 200 mg Troche (Clinic)",
      "subtitle": "Recall D-0814-2020",
      "detail": "Reason: Labeling: Incorrect or missing lot and/or expiration date. Products were compounded using expired components.",
      "status": "Class II · Terminated",
      "fields": {
        "recordType": "Recall",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "classification": "Class II",
        "firm": "MPRX, Inc. dba Medical Park Pharmacy",
        "recallNumber": "D-0814-2020"
      },
      "jurisdiction": "US",
      "date": "2020-02-05T00:00:00.000Z",
      "dateType": "Enforcement report date",
      "source": {
        "title": "Class II recall: Sildenafil 200 mg Troche (Clinic)",
        "url": "https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0814-2020%22",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:12.440Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:28.173Z",
      "change": {
        "note": "Recall published in the FDA Enforcement Report",
        "at": "2020-02-05T00:00:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:119",
      "record": "Magic Bullet Supplement",
      "subtitle": "Recall D-0809-2020",
      "detail": "Reason: Labeling: Incorrect or missing lot and/or expiration date. Products were compounded using expired components.",
      "status": "Class II · Terminated",
      "fields": {
        "recordType": "Recall",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "classification": "Class II",
        "firm": "MPRX, Inc. dba Medical Park Pharmacy",
        "recallNumber": "D-0809-2020"
      },
      "jurisdiction": "US",
      "date": "2020-02-05T00:00:00.000Z",
      "dateType": "Enforcement report date",
      "source": {
        "title": "Class II recall: Magic Bullet Supplement",
        "url": "https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0809-2020%22",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:12.440Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:28.215Z",
      "change": {
        "note": "Recall published in the FDA Enforcement Report",
        "at": "2020-02-05T00:00:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:118",
      "record": "Finasteride/Biotin 1 mg/50 mcg",
      "subtitle": "Recall D-0804-2020",
      "detail": "Reason: Labeling: Incorrect or missing lot and/or expiration date. Products were compounded using expired components.",
      "status": "Class II · Terminated",
      "fields": {
        "recordType": "Recall",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "classification": "Class II",
        "firm": "MPRX, Inc. dba Medical Park Pharmacy",
        "recallNumber": "D-0804-2020"
      },
      "jurisdiction": "US",
      "date": "2020-02-05T00:00:00.000Z",
      "dateType": "Enforcement report date",
      "source": {
        "title": "Class II recall: Finasteride/Biotin 1 mg/50 mcg",
        "url": "https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0804-2020%22",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:12.440Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:28.253Z",
      "change": {
        "note": "Recall published in the FDA Enforcement Report",
        "at": "2020-02-05T00:00:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:117",
      "record": "Testosterone Topical Cream 4%",
      "subtitle": "Recall D-0820-2020",
      "detail": "Reason: Labeling: Incorrect or missing lot and/or expiration date. Products were compounded using expired components.",
      "status": "Class II · Terminated",
      "fields": {
        "recordType": "Recall",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "classification": "Class II",
        "firm": "MPRX, Inc. dba Medical Park Pharmacy",
        "recallNumber": "D-0820-2020"
      },
      "jurisdiction": "US",
      "date": "2020-02-05T00:00:00.000Z",
      "dateType": "Enforcement report date",
      "source": {
        "title": "Class II recall: Testosterone Topical Cream 4%",
        "url": "https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0820-2020%22",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:12.440Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:28.290Z",
      "change": {
        "note": "Recall published in the FDA Enforcement Report",
        "at": "2020-02-05T00:00:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:116",
      "record": "Progesterone E4M SR 100 mg capsules",
      "subtitle": "Recall D-0813-2020",
      "detail": "Reason: Labeling: Incorrect or missing lot and/or expiration date. Products were compounded using expired components.",
      "status": "Class II · Terminated",
      "fields": {
        "recordType": "Recall",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "classification": "Class II",
        "firm": "MPRX, Inc. dba Medical Park Pharmacy",
        "recallNumber": "D-0813-2020"
      },
      "jurisdiction": "US",
      "date": "2020-02-05T00:00:00.000Z",
      "dateType": "Enforcement report date",
      "source": {
        "title": "Class II recall: Progesterone E4M SR 100 mg capsules",
        "url": "https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0813-2020%22",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:12.440Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:28.326Z",
      "change": {
        "note": "Recall published in the FDA Enforcement Report",
        "at": "2020-02-05T00:00:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:115",
      "record": "Sildenafil 80 mg capsules",
      "subtitle": "Recall D-0815-2020",
      "detail": "Reason: Labeling: Incorrect or missing lot and/or expiration date. Products were compounded using expired components.",
      "status": "Class II · Terminated",
      "fields": {
        "recordType": "Recall",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "classification": "Class II",
        "firm": "MPRX, Inc. dba Medical Park Pharmacy",
        "recallNumber": "D-0815-2020"
      },
      "jurisdiction": "US",
      "date": "2020-02-05T00:00:00.000Z",
      "dateType": "Enforcement report date",
      "source": {
        "title": "Class II recall: Sildenafil 80 mg capsules",
        "url": "https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0815-2020%22",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:12.440Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:28.364Z",
      "change": {
        "note": "Recall published in the FDA Enforcement Report",
        "at": "2020-02-05T00:00:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:114",
      "record": "Lidocaine/Priloc/PE 30/5/0.25% 30 GM jars",
      "subtitle": "Recall D-0806-2020",
      "detail": "Reason: Labeling: Incorrect or missing lot and/or expiration date. Products were compounded using expired components.",
      "status": "Class II · Terminated",
      "fields": {
        "recordType": "Recall",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "classification": "Class II",
        "firm": "MPRX, Inc. dba Medical Park Pharmacy",
        "recallNumber": "D-0806-2020"
      },
      "jurisdiction": "US",
      "date": "2020-02-05T00:00:00.000Z",
      "dateType": "Enforcement report date",
      "source": {
        "title": "Class II recall: Lidocaine/Priloc/PE 30/5/0.25% 30 GM jars",
        "url": "https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0806-2020%22",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:12.440Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:28.404Z",
      "change": {
        "note": "Recall published in the FDA Enforcement Report",
        "at": "2020-02-05T00:00:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:113",
      "record": "Lidocaine/Priloc/PE 15/5/0.25% 30 GM jars",
      "subtitle": "Recall D-0805-2020",
      "detail": "Reason: Labeling: Incorrect or missing lot and/or expiration date. Products were compounded using expired components.",
      "status": "Class II · Terminated",
      "fields": {
        "recordType": "Recall",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "classification": "Class II",
        "firm": "MPRX, Inc. dba Medical Park Pharmacy",
        "recallNumber": "D-0805-2020"
      },
      "jurisdiction": "US",
      "date": "2020-02-05T00:00:00.000Z",
      "dateType": "Enforcement report date",
      "source": {
        "title": "Class II recall: Lidocaine/Priloc/PE 15/5/0.25% 30 GM jars",
        "url": "https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0805-2020%22",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:12.440Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:28.445Z",
      "change": {
        "note": "Recall published in the FDA Enforcement Report",
        "at": "2020-02-05T00:00:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:112",
      "record": "Naltrexone 4.5 mg capsule",
      "subtitle": "Recall D-0810-2020",
      "detail": "Reason: Labeling: Incorrect or missing lot and/or expiration date. Products were compounded using expired components.",
      "status": "Class II · Terminated",
      "fields": {
        "recordType": "Recall",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "classification": "Class II",
        "firm": "MPRX, Inc. dba Medical Park Pharmacy",
        "recallNumber": "D-0810-2020"
      },
      "jurisdiction": "US",
      "date": "2020-02-05T00:00:00.000Z",
      "dateType": "Enforcement report date",
      "source": {
        "title": "Class II recall: Naltrexone 4.5 mg capsule",
        "url": "https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0810-2020%22",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:12.440Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:28.485Z",
      "change": {
        "note": "Recall published in the FDA Enforcement Report",
        "at": "2020-02-05T00:00:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:111",
      "record": "Tadalafil 6 mg Capsule",
      "subtitle": "Recall D-0819-2020",
      "detail": "Reason: Labeling: Incorrect or missing lot and/or expiration date. Products were compounded using expired components.",
      "status": "Class II · Terminated",
      "fields": {
        "recordType": "Recall",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "classification": "Class II",
        "firm": "MPRX, Inc. dba Medical Park Pharmacy",
        "recallNumber": "D-0819-2020"
      },
      "jurisdiction": "US",
      "date": "2020-02-05T00:00:00.000Z",
      "dateType": "Enforcement report date",
      "source": {
        "title": "Class II recall: Tadalafil 6 mg Capsule",
        "url": "https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0819-2020%22",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:12.440Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:28.521Z",
      "change": {
        "note": "Recall published in the FDA Enforcement Report",
        "at": "2020-02-05T00:00:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:110",
      "record": "Progesterone 200 mg Troche",
      "subtitle": "Recall D-0811-2020",
      "detail": "Reason: Labeling: Incorrect or missing lot and/or expiration date. Products were compounded using expired components.",
      "status": "Class II · Terminated",
      "fields": {
        "recordType": "Recall",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "classification": "Class II",
        "firm": "MPRX, Inc. dba Medical Park Pharmacy",
        "recallNumber": "D-0811-2020"
      },
      "jurisdiction": "US",
      "date": "2020-02-05T00:00:00.000Z",
      "dateType": "Enforcement report date",
      "source": {
        "title": "Class II recall: Progesterone 200 mg Troche",
        "url": "https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0811-2020%22",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:12.440Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:28.558Z",
      "change": {
        "note": "Recall published in the FDA Enforcement Report",
        "at": "2020-02-05T00:00:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    },
    {
      "key": "item:109",
      "record": "Squaric Acid 0.1% Topical Solution (Clinic) 30 mL",
      "subtitle": "Recall D-0816-2020",
      "detail": "Reason: Labeling: Incorrect or missing lot and/or expiration date. Products were compounded using expired components.",
      "status": "Class II · Terminated",
      "fields": {
        "recordType": "Recall",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "classification": "Class II",
        "firm": "MPRX, Inc. dba Medical Park Pharmacy",
        "recallNumber": "D-0816-2020"
      },
      "jurisdiction": "US",
      "date": "2020-02-05T00:00:00.000Z",
      "dateType": "Enforcement report date",
      "source": {
        "title": "Class II recall: Squaric Acid 0.1% Topical Solution (Clinic) 30 mL",
        "url": "https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0816-2020%22",
        "publisher": "U.S. Food and Drug Administration (Enforcement Report)",
        "type": "Official record"
      },
      "lastChecked": "2026-10-01T09:05:12.440Z",
      "checkedBy": "system",
      "nphlaUpdatedAt": "2026-10-01T09:05:28.595Z",
      "change": {
        "note": "Recall published in the FDA Enforcement Report",
        "at": "2020-02-05T00:00:00.000Z",
        "withinLast7Days": false
      },
      "origin": "automated"
    }
  ]
}